1-11 of 11
Deborah Hurst
Close
Sort by
Journal Articles

Big Data Analysis of Treatment Patterns and Outcomes Among Elderly Medicare Acute Myeloid Leukemia Patients

Sacha Satram-Hoang, PhD, Carolina Reyes, PhD, Khang Q. Hoang, DO, Faiyaz Momin, MS, Deborah Hurst, MD, Bruno C Medeiros, MD
Journal: Blood
Blood (2014) 124 (21): 3698.
https://doi.org/10.1182/blood.V124.21.3698.3698
Published: 2014
Journal Articles

Real-World Outcomes Among Elderly Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Bruno C Medeiros, MD, Sacha Satram-Hoang, PhD, Khang Q. Hoang, DO, Faiyaz Momin, MS, Deborah Hurst, MD, Carolina Reyes, PhD
Journal: Blood
Blood (2014) 124 (21): 2271.
https://doi.org/10.1182/blood.V124.21.2271.2271
Published: 2014
Journal Articles

Comparative Effectiveness of Chemotherapy in an Elderly Acute Myeloid Leukemia Population in the United States

Bruno C Medeiros, MD, Sacha Satram-Hoang, PhD, Khang Q. Hoang, DO, Faiyaz Momin, MS, Deborah Hurst, MD, Carolina Reyes, PhD
Journal: Blood
Blood (2014) 124 (21): 2272.
https://doi.org/10.1182/blood.V124.21.2272.2272
Published: 2014
Journal Articles

Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Herbert Eradat, MD, MS, Sebastian Grosicki, MD, PhD, John Catalono, MD, Walter Cosolo, MD, Irina Dyagil, Thomas J Kipps, MD, PhD, Beiyao Zheng, Sreeni Yalamanchili, Srikumar Sahasranaman, Deborah Hurst, MD, William Ho, MD, PhD, Halyna Pylypenko, MD
Journal: Blood
Blood (2012) 120 (21): 190.
https://doi.org/10.1182/blood.V120.21.190.190
Published: 2012
Journal Articles

Final Results of a Single Arm Phase III Multicenter, Open-Label Study of Rituximab Administered by Faster Infusion in Patients with Previously Untreated Diffuse Large-B Cell (DLBCL) or Follicular Non-Hodgkin's Lymphoma (FL)

Shaker R. Dakhil, MD, Robert Hermann, MD, Akiko Chai, MS, Deborah Hurst, MD, Gregg Fine, MD, Paul Richards, MD
Journal: Blood
Blood (2011) 118 (21): 2703.
https://doi.org/10.1182/blood.V118.21.2703.2703
Published: 2011
Journal Articles

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Annika Dufour, MD, S. K Bohlander, PhD, Karsten Spiekermann, MD, Stephanie Schneider, Jan Braess, MD, Purvi Kakadiya, Kirsten E Mundt, PhD, Helen Smith, Ming Lin, PhD, Martin Barrett, PhD, Deborah Hurst, MD, Anna Dmoszynska, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Boris V Afanasiev, MD, John Catalano, MBBS, FRACP, FRCPA, Marco Montillo, Christian H. Geisler, MD, Sergey I Moiseev, MD, Philippe Solal-Celigny, MD, Tadeusz Robak, Wolfgang Hiddemann, MD
Journal: Blood
Blood (2010) 116 (21): 1390.
https://doi.org/10.1182/blood.V116.21.1390.1390
Published: 2010
Journal Articles

Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

John C. Byrd, MD, Ian W. Flinn, MD, Khuda D. Khan, MD, Thomas J. Kipps, MD, Lea Aukerman, PhD, Judith Fox, PhD, Sandhya Girish, PhD, Serge Guzy, PhD, Sanela Bilic, PharmD, Alan Solinger, MD, Sherri Dort, BS, Yongyu Wang, MD, Deborah Hurst, MD, Susan O’Brien, MD
Journal: Blood
Blood (2006) 108 (11): 2837.
https://doi.org/10.1182/blood.V108.11.2837.2837
Published: 2006
Journal Articles

A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma.

William Bensinger, MD, Sundar Jagannath, MD, Pamela S. Becker, MD, PhD, Kenneth C. Anderson, MD, Edward A. Stadtmauer, MD, Lea Aukerman, PhD, Judith Fox, PhD, Sandhya Girish, PhD, Sanela Bilic, PharmD, Serge Guzy, PhD, Alan Solinger, MD, Sherri Dort, BS, Yongyu Wang, MD, Deborah Hurst, MD
Journal: Blood
Blood (2006) 108 (11): 3575.
https://doi.org/10.1182/blood.V108.11.3575.3575
Published: 2006
Journal Articles

Comparison of Pharmacokinetics and Pharmacodynamics of two different dosing regimens of Proleukin® (IL-2) in Combination with rituximab: The effect of NK cell expansion.

Sandra Milan, Deborah Hurst, Glenn Michelson, Emil Samara
Journal: Blood
Blood (2004) 104 (11): 4627.
https://doi.org/10.1182/blood.V104.11.4627.4627
Published: 2004
Journal Articles

Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion

Jerry S. Powell, Margaret V. Ragni, Gilbert C. White, II, Jeanne M. Lusher, Carol Hillman-Wiseman, Tom E. Moon, Veronica Cole, Sandhya Ramanathan-Girish, Holger Roehl, Nancy Sajjadi, Douglas J. Jolly, Deborah Hurst
Journal: Blood
Blood (2003) 102 (6): 2038–2045.
https://doi.org/10.1182/blood-2003-01-0167
Published: 2003
Journal Articles

The Inhibitor Antibody Response Is More Complex in Hemophilia A Patients Than in Most Nonhemophiliacs With Factor VIII Autoantibodies

Richard Prescott, Hiroaki Nakai, Evgueni L. Saenko, Inge Scharrer, Inga Marie Nilsson, John E. Humphries, Deborah Hurst, Gordon Bray, Dorothea Scandella, the Recombinate and Kogenate Study Groups
Journal: Blood
Blood (1997) 89 (10): 3663–3671.
https://doi.org/10.1182/blood.V89.10.3663
Published: 1997